The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial
Abstract
Background Based on the early results of the Placement of Aortic Transcatheter Valves (PARTNER) trial, transcatheter aortic valve replacement (TAVR) is an accepted treatment for patients with severe aortic stenosis who are not suitable for surgery. However, little information is available about the late clinical outcomes in such patients.Methods We did this randomised controlled trial at 21 experienced valve centres in Canada, Germany, and the USA. We enrolled patients with severe symptomatic inoperable aortic stenosis and randomly assigned (1:1) them to transfemoral TAVR or to standard treatment, which often included balloon aortic valvuloplasty. Patients and their treating physicians were not masked to treatment allocation. The randomisation was done centrally, and sites learned of the assignment only after a patient had been screened, consented, and entered into the database. The primary outcome of the trial was all-cause mortality at 1 year in the intention-to-treat population, here we present the prespecified findings after 5 years. This study is registered with ClinicalTrials.gov, number NCT00530894.Findings We screened 3015 patients, of whom 358 were enrolled (mean age 83 years, Society of Thoracic Surgeons Predicted Risk of Mortality 11·7%, 54% female). 179 were assigned to TAVR treatment and 179 were assigned to standard treatment. 20 patients crossed over from the standard treatment group and ten withdrew from study, leaving only six patients at 5 years, of whom five had aortic valve replacement treatment outside of the study. The risk of all-cause mortality at 5 years was 71·8% in the TAVR group versus 93·6% in the standard treatment group (hazard ratio 0·50, 95% CI 0·39-0·65; p<0·0001). At 5 years, 42 (86%) of 49 survivors in the TAVR group had New York Heart Association class 1 or 2 symptoms compared with three (60%) of five in the standard treatment group. Echocardiography after TAVR showed durable haemodynamic benefit (aortic valve area 1·52 cm(2) at 5 years, mean gradient 10·6 mm Hg at 5 years), with no evidence of structural valve deterioration.Interpretation TAVR is more beneficial than standard treatment for treatment of inoperable aortic stenosis. TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status. Appropriate selection of patients will help to maximise the benefit of TAVR and reduce mortality from severe comorbidities.Funding Edwards Lifesciences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For patients at high or prohibitive risk of operative mortality, with surgical AVR, TAVR has been a transformative innovation, providing a life-saving treatment for patients who were previously not candidates for AVR”
From Calcific aortic stenosis (2016) · cites this paper as [222]
Citations
Cites
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008232 · Cited by 7,205
Self-citationTwo-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
Kodali, S. K., Williams, M. R., Smith, C. R., Svensson, L. G., Webb, J. G., Makkar, R. R., Fontana, G. P., Dewey, T. M., Thourani, V. H., Pichard, A. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200384 · Cited by 2,282
Self-citationTranscatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis
Makkar, R. R., Fontana, G. P., Jilaihawi, H., Kapadia, S., Pichard, A. D., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Webb, J. G., Herrmann, H. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202277 · Cited by 1,342
Self-citationRodés-Cabau, J., Webb, J. G., Cheung, A., Ye, J., Dumont, E., Feindel, C. M., Osten, M., Natarajan, M. K., Velianou, J. L., Martucci, G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.014 · Cited by 974
Self-citationMoat, N. E., Ludman, P., de Belder, M. A., Bridgewater, B., Cunningham, A. D., Young, C. P., Thomas, M., Kovac, J., Spyt, T., MacCarthy, P. A., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.050 · Cited by 884
Thomas, M., Schymik, G., Walther, T., Himbert, D., Lefèvre, T., Treede, H., Eggebrecht, H., Rubino, P., Colombo, A., Lange, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.001545 · Cited by 524
Vascular Complications After Transcatheter Aortic Valve Replacement
Généreux, P., Webb, J. G., Svensson, L. G., Kodali, S. K., Satler, L. F., Fearon, W. F., Davidson, C. J., Eisenhauer, A. C., Makkar, R. R., Bergman, G. W., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.003 · Cited by 518
Self-citationOutcomes Following Transcatheter Aortic Valve Replacement in the United States
Mack, M. J., Brennan, J. M., Brindis, R., Carroll, J., Edwards, F., Grover, F., Shahian, D., Tuzcu, E. M., Peterson, E. D., Rumsfeld, J. S., et al. (2013) · JAMA · doi:10.1001/jama.2013.282043 · Cited by 474
Self-citationGreen, P., Woglom, A. E., Genereux, P., Daneault, B., Paradis, J.-M., Schnell, S., Hawkey, M., Maurer, M. S., Kirtane, A. J., Kodali, S., et al. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.06.011 · Cited by 473
Self-citationMiller, D. C., Blackstone, E. H., Mack, M. J., Svensson, L. G., Kodali, S. K., Kapadia, S., Rajeswaran, J., Anderson, W. N., Moses, J. W., Tuzcu, E. M., et al. (2012) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.01.055 · Cited by 343
Self-citation
Research works printed but not linked: 2
- Ross, 1968, Aortic stenosis, Circulation, 38, 61
- Genereux, 2012, Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial, J Am Coll Cardiol, 60, 1043, 10.1016/j.jacc.2012.07.003 · DOI · Paper page
Cited by
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Leon, M. B., Smith, C. R., Mack, M. J., Makkar, R. R., Svensson, L. G., Kodali, S. K., Thourani, V. H., Tuzcu, E. M., Miller, D. C., Herrmann, H. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514616 · Cited by 5,053
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Mack, M. J., Leon, M. B., Thourani, V. H., Makkar, R., Kodali, S. K., Russo, M., Kapadia, S. R., Malaisrie, S. C., Cohen, D. J., Pibarot, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814052 · Cited by 4,847
Self-citationOtto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Self-citation
Metadata
- Authors
- Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., Webb, J. G., Mack, M. J., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Herrmann, H. C., Szeto, W. Y., Pichard, A. D., Williams, M. R., Fontana, G. P., Miller, D. C., Anderson, W. N., Smith, C. R., Akin, J. J., & Davidson, M. J.
- Affiliations
- Cleveland Clinic (US)
- NewYork–Presbyterian Hospital (US)
- Cedars-Sinai Medical Center (US)
- St. Paul's Hospital (CA)
- Baylor Scott & White Health (US)
- Duke Medical Center (US)
- Emory University (US)
- University of Pennsylvania (US)
- MedStar Washington Hospital Center (US)
- NYU Langone Health (US)
- Lenox Hill Hospital (US)
- Stanford Medicine (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Kapadia, Samir R
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 385
- Issue
- 9986
- Pages
- 2485-2491
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2109553540
- Cited by
- 867
- References
- 23
- Citations by year
- 2026: 37 · 2025: 53 · 2024: 39 · 2023: 55 · 2022: 50 · 2021: 70 · 2020: 84 · 2019: 94 · 2018: 107 · 2017: 118 · 2016: 114 · 2015: 40
- FWCI
- 91.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Vascular
- Medtronic
- St. Jude Medical
- National Heart, Lung, and Blood Institute (67025)
- Edwards Lifesciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Aortic Disease and Treatment Approaches
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- transcatheter aortic valve implantation, severe aortic stenosis, all-cause mortality, long-term outcomes, balloon aortic valvuloplasty, standard treatment, transfemoral access, NYHA functional class, aortic valve area, haemodynamic outcomes, PARTNER trial, elderly patients
- MeSH terms
- Aged, Aged, 80 and over, Aortic Valve, Aortic Valve Stenosis, Canada, Cause of Death, Echocardiography, Female, Follow-Up Studies, Germany, Hemodynamics, Humans, Male, United States, Comorbidity, Survival Rate, Treatment Outcome, Risk Assessment, Stroke, Kaplan-Meier Estimate, Transcatheter Aortic Valve Replacement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)60290-2
- The paper
- Kapadia, S. R., Leon, M. B., Makkar, R. R., Tuzcu, E. M., Svensson, L. G., Kodali, S., Webb, J. G., Mack, M. J., Douglas, P. S., Thourani, V. H., Babaliaros, V. C., Herrmann, H. C., Szeto, W. Y., Pichard, A. D., Williams, M. R., Fontana, G. P., Miller, D. C., Anderson, W. N., Smith, C. R., . . . Davidson, M. J. (2015). 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)60290-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.